Should a young adult male patient with Philadelphia-like ALL being treated on the Alliance A041501 protocol and in remission undergo transplant?   

Transplant is not part of the trial but is the standard outside of the trial. A041501 is a phase III trial to evaluate the efficacy of the addition of Inotuzumab Ozogamicin (a conjugated anti-CD22 monoclonal antibody) to frontline therapy in young adults (ages 18-39 years) with newly diagnosed precursor B-Cell ALL.